| Code | CSB-RA011661MB5HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to dupilumab, targeting the interleukin-4 receptor (IL4R). IL4R is a type I transmembrane protein that serves as a shared receptor subunit for both IL-4 and IL-13, two key cytokines that drive type 2 inflammatory responses. Upon ligand binding, IL4R initiates signaling cascades that promote IgE production, mucus secretion, and eosinophil recruitment. Dysregulated IL4R signaling is implicated in various allergic and inflammatory conditions, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis.
Dupilumab is a fully humanized monoclonal antibody that specifically binds to the IL4Rα subunit, thereby blocking the signaling of both IL-4 and IL-13. This biosimilar antibody provides researchers with a valuable tool for investigating type 2 immune responses, studying the molecular mechanisms underlying allergic inflammation, and exploring therapeutic interventions in preclinical disease models. It enables examination of IL4R pathway modulation and its downstream effects on immune cell function and inflammatory mediator production.
There are currently no reviews for this product.